Migraine is one of the most common neurological disorders and affects millions of people worldwide. With the development of CGRP-targeted therapies – monoclonal antibodies and Gepanten – the treatment of this widespread disease has experienced a turning point in recent years. These substances are highly effective, have a favorable side-effect profile and are clearly pathophysiologically targeted. However, one patient group remains cautious: people with vascular risk factors or who have already suffered cerebrovascular disease. Particularly in this group, which was often excluded from clinical trials, crucial questions arise: How safe is blockade of the CGRP system really? What data is available and where are there still gaps?
You May Also Like
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- COPD therapy
Drug therapy – Update 2025
- Focus on prevention
Colorectal cancer screening – an update
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making